ONCOIMMUNITY
OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines and cell therapies in a clinically actionable time-frame. Headquartere... d at the Oslo Cancer Cluster Incubator (OCCI), Norway, OncoImmunity AS is a private company founded in 2014 and is backed by capital financing from the Norwegian Radiumhospital Research Foundation (RadForsk), the Norwegian Cancer Society, STARTUPLAB, Grotmol Solutions, and a number of private investors.
ONCOIMMUNITY
Industry:
Biotechnology Health Care Medical
Founded:
2014-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.oncoimmunity.com
Total Employee:
1+
Status:
Active
Contact:
47 90 01 52 42
Total Funding:
2.25 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Universal Analytics Font Awesome Domain Not Resolving Mobile Non Scaleable Content Amazon Google Maps
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Intelligent Agent
Intelligent Agent is a young and innovative company based in Oslo, Norway.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - OncoImmunity
Official Site Inspections
http://www.oncoimmunity.com
- Host name: lb01.domeneshop.no
- IP address: 194.63.249.220
- Location: Norway
- Latitude: 59.9452
- Longitude: 10.7559
- Timezone: Europe/Oslo
More informations about "OncoImmunity"
NEC OncoImmunity AS
NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy . 4th Sep 2023. …See details»
About NEC OncoImmunity AS
About NEC OncoImmunity AS Robust & reliable neoantigen prediction to empower the next generation cancer immunotherapies. NEC OncoImmunity AS is an artificial intelligence (AI) …See details»
NEC OncoImmunity AS - Crunchbase Company Profile & Funding
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction …See details»
NEC OncoImmunity AS - The Hub
OncoImmunity’s technology will disrupt the I-O field by offering regulatory-compliant prediction software on a software-as-a-service basis (SaaS). This will allow big pharma, biotechnology, and immunotherapy companies of any size …See details»
NEC OncoImmunity AS - LinkedIn
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning software, which addresses the key gaps in the prediction of bona fide ...See details»
NEC Establishes Subsidiaries in Europe for Strengthening Global AI …
Mar 31, 2023 Dr. Richard Stratford, CEO of NEC OncoImmunity, said: “This new organization is vital for further growth in the drug development space. NEC OncoImmunity will continue its …See details»
NEC acquires Norwegian bioinformatics company, OncoImmunity AS
Tokyo, July 29, 2019 - NEC Corporation (NEC; TSE: 6701) today announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary …See details»
NEC and OncoImmunity AS combine forces to use AI to empower ...
About OncoImmunity AS. OncoImmunity AS is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bona …See details»
ONCOIMMUNITY AS - VentureRadar
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction …See details»
OncoImmunity - Overview, News & Similar companies - ZoomInfo
Who is OncoImmunity. NEC OncoImmunity AS is a bioinformatics company offering proprietary machine learning-based software called the NEC Immune Profiler, which addresse s the key …See details»
CEPI partners with Japan's NEC Group to develop artificial …
Apr 8, 2022 -University of Saskatchewan's Vaccine and Infectious Disease Organization ... NEC OncoImmunity AS is an AI driven biotechnology company that has developed proprietary …See details»
Nagasaki University and NEC OncoImmunity Collaborate to Design ...
Aug 21, 2023 Nagasaki, Japan, Oslo, Norway, August 21, 2023: Nagasaki University and NEC OncoImmunity (NOI), a leading artificial intelligence ... Endemics, affiliated with Nagasaki …See details»
OncoImmunity - The Hub
OncoImmunity develops machine-learning methods for personalized cancer medicine. Our flagship product predicts a patient response to cancer immunotherapy, from genomic data. We …See details»
Our Technology | NEC OncoImmunity AS
The proprietary developments by the NEC OncoImmunity team fills the existing machine-learning gaps and predicts antigen presentation to the cell surface to facilitate the automated screening …See details»
OncoImmunity - Company Profile - Tracxn
Oct 25, 2024 OncoImmunity ranks 44th among 271 active competitors. 97 of its competitors are funded while 10 have exited. Overall, OncoImmunity and its competitors have raised over …See details»
NEC OncoImmunity Publishes a Unique HLA Typing Technology …
Feb 17, 2022 NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge …See details»
OncoImmunity and the Norwegian Cancer Genomics Consortium …
OncoImmunity and the Norwegian Cancer Genomics Consortium team up with the US SARC organization to explore predictive neoantigen biomarkers of checkpoint inhibition using …See details»
The Basis of OncoImmunology - PMC
Cancer heterogeneity, which enables clonal survival and treatment resistance, is shaped by active immune responses. Antigen-specific T cells can control cancer, as revealed clinically by …See details»
Transgene and NEC Announce Positive Preliminary Data
Nov 22, 2021 NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy . 4th Sep …See details»
NEC OncoImmunity News | NEC OncoImmunity AS
Latest research and company news from NEC OncoImmunity.See details»